Altimmune, Inc. (NYSE:ALT) Receives Consensus Rating of “Strong Buy” from Brokerages
Shares of Altimmune, Inc. (NYSE:ALT) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports.
Analysts have set a 1-year consensus price objective of $10.00 for the company, according to Zacks. Zacks has also assigned Altimmune an industry rank of 81 out of 256 based on the ratings given to related companies.
NYSE ALT opened at $2.35 on Friday. Altimmune has a 1 year low of $1.70 and a 1 year high of $36.25.
Altimmune Company Profile
Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.
Read More: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.